


Can External Use of Chinese Herbal Medicine Prevent Cumulative Peripheral Neuropathy Induced by Oxaliplatin? A Systematic Literature Review With Meta-analysis

Integrative Cancer Therapies
Volume 18: 1–15
© The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1534735419872819
journals.sagepub.com/home/ict


Jie Hao, BMED, MMed¹, Xiaoshu Zhu, PhD¹, Caroline A. Smith, PhD¹, and Alan Bensoussan, PhD¹

Abstract

Background. Peripheral neurotoxicity caused by oxaliplatin (OXA) chemotherapy is the main limitation preventing continuation of chemotherapy in patients with gastrointestinal cancer. The purpose of this study was to determine the efficacy of external use of Chinese herbal medicine (CHM) on the incidence of cumulative OXA-induced peripheral neurotoxicity (OIPN). *Method.* Scientific literature databases were searched to identify controlled clinical trials analyzing CHM in OIPN. Clinical studies that included at least 1 relevant primary outcome were analyzed by 2 independent reviewers. Meta-analysis was performed on the software RevMan 5.3. *Results.* 700 cancer patients of 9 studies were reported, of whom 352 received external CHM and 348 received warm water baths, conventional medicine, or no intervention as controls. Neurotoxicity incidence (Levi grade ≥ 1) was significantly decreased in CHM group, compared with no intervention ($P < .01$). The incidence of cumulative neurotoxicity (Levi grade ≥ 2) was also significantly lower in the CHM group than in all the control groups ($P < .05$), and the cumulative neurotoxicity in the CHM group was significantly reduced (Levi grade ≥ 3) in comparison with no intervention ($P < .01$). These results were consistent with those of the subgroup analyses for preventing OIPN at each of the chemotherapy treatment cycles. There was no difference in the incidence of adverse events between groups ($P > .05$). *Conclusion.* External use of CHM may be beneficial in preventing the OXA-induced cumulative neurotoxicity. However, given the low quality of the evidence, the results should be interpreted with caution.

Keywords

oxaliplatin-induced peripheral neuropathy, Chinese herbal medicine, prevention, systematic review, meta-analysis

Submitted April 22, 2019; revised July 12, 2019; accepted August 7, 2019

Introduction

Oxaliplatin (OXA) is a chemotherapeutic agent frequently prescribed to treat gastrointestinal cancer.¹ However, neurotoxicity induced by OXA is a common side effect². In general, OXA-induced peripheral neurotoxicity (OIPN) occurs when OXA infusion is continued for 4 or more cycles.^{3,4} High cumulative doses of OXA have a concomitant increase in chronic peripheral nerve damage. The incidence of chronic peripheral neuropathy can be up to 85%.^{4,5} Clinical symptoms are characterized by distal sensory loss,

suppression of deep tendon reflexes, and changes in proprioception.^{6,7} These side effects not only affect a patient's quality of life,⁸⁻¹⁰ but also limit patient compliance with cancer treatment. This can result in OXA dose reduction and discontinuation.^{5,11} Strategies for preventing

¹Western Sydney University, Sydney, NSW, Australia

Corresponding Author:

Xiaoshu Zhu, Western Sydney University, Sydney, NSW, Australia.
Email: X.Zhu@westernsydney.edu.au



cumulative OIPN currently include intravenous calcium and magnesium, glutathione, venlafaxine, and calmetaglifipir.¹²⁻¹⁴ However, pharmacological management is limited, and there is a lack of consensus on optimal prevention strategies.¹²⁻¹⁴

There is a growing interest in the use of complementary medicine to help individuals manage their cancer treatment journey and survivorship.¹⁵ Chinese medicine plays an important role in cancer care in China.¹⁶ Based on its own distinctive principles and comprehensive theory, it is also one of the oldest medical systems in the world. Chinese herbal hand and foot baths administered periodically over several weeks have been used in China for the management of OIPN. Topical Chinese herbal medicine (CHM) therapy exerts its effect through the skin with relatively minimal systemic uptake or distribution. Recent reviews have reported on the use of herbal medicines (including CHMs) for chemotherapy-induced peripheral neuropathy.¹⁷⁻²⁰ However, interpretation of the evidence from these reviews was limited by the inclusion of quasi-randomized controlled trials (RCTs), variation in the form and dosing characteristics of the intervention, and poor reporting. The primary aim of our systematic review is to provide an update of the evidence describing the effectiveness and safety of external use of CHM for preventing chronic OXA-induced peripheral neuropathy.

Methods

Our systematic review adopts the preferred reporting protocol for systematic reviews and meta-analyses as outlined by the PRISMA statement (Appendix).²¹ The review protocol was registered in PROSPERO (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=94301).

Search Strategy

A comprehensive search was conducted to identify all relevant studies regardless of language or publication status. Databases searched included MEDLINE, EMBASE, CINAHL, The Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials), and Chinese databases China National Knowledge Infrastructure (CNKI), Wangfang, and VIP. All databases were searched from inception to November 2018. MEDLINE and CNKI search strategies are shown in Appendix.

Eligibility Criteria

RCTs were included without restriction of language. For articles not published in English or Chinese, translators were used. Crossover studies were generally excluded because of potential carryover effects.

Studies were included if patients were >18 years old, with any type of cancer and receiving OXA regimens over at least 4 cycles. Patients were excluded if they had a history of peripheral neuropathy resulting from any cause or any coexisting condition that could impair peripheral nerve function. Permitted control groups included placebo-designed herbal baths, warm water baths, conventional medicine (eg, intravenous calcium and magnesium, mecabalamin), or no intervention. Studies that added or compared external CHM with additional unknown potentially active treatments (eg, wash, gel, or cream) were excluded. Clinical studies that included at least 1 relevant primary outcome were eligible for analysis.

The primary outcome was the incidence of neurotoxicity measured by standardized and validated clinical assessment tools. These tools included, but were not limited to, patient-reported outcomes, clinician-rated neuropathy assessments, and functional measures (eg, nerve conduction velocity [NCV]). In this review, the clinician-rated neuropathy assessments used the World Health Organization (WHO) Common Toxicity Criteria for Peripheral Neuropathy, National Cancer Institute Common Toxicity Criteria (NCI-CTC), the Levi grade, and Toronto Clinical Neuropathy Score. Secondary outcomes included safety outcomes (eg, adverse event reporting), performance/functionality measures, OXA dosage associated with time to neuropathy and its severity, and discontinuation or change in OXA dosage caused by OIPN. We also considered subgroup analysis for these outcomes at different time points (number of cycles) of chemotherapy, if data were available.

Data Extraction

The relevant data were extracted by 2 authors (JH and XZ) working independently, including patient demographics and cancer types, chemotherapy types, and the effect of the intervention and the control on OXA-related neurotoxicity (Table 1).

Statistical Methods

RevMan 5.3 software was used for the meta-analysis.²² Dichotomous variables were analyzed with odds ratios (ORs) and continuous outcomes with mean differences (MDs) at a 95% CI. Two-sided *P* values were computed for the differences between dichotomous variables and continuous variables, which were considered significant at *P* < .05. The random-effects model (the DerSimonian and Laird method) or fixed-effects model (the Mantel-Haenszel method) was used for variables of heterogeneity, when explored using the χ^2 test with significance set at *P* \leq .100 or *P* > .100, respectively.²³ Further analyses of available outcomes were performed at each of the chemotherapy treatment cycles to verify the accuracy of the results. The

Table 1. Summary of the Included Randomized Controlled Trials of External Chinese Herbal Medicine for Preventing OIPN.

First Author (Year)	Sample Size (Dropouts)	Mean Age (Median range)	Women:Men (Percentage Men)	Type of Cancer	Common Treatment in Both Groups (Regimen)	Cumulative Oxaliplatin Dose	Intervention Group (Regimen, Participants)	Control Group (Regimen, Participants)	Primary and Secondary Outcomes	Intergroup Differences at the End	Follow-up
Chen (2017)	90 (0)	57 (40-76)	43:47 (52%)	Gastric cancer: 49; colorectal cancer: 41	XELOX (130mg/m ² , 3 wk/cycle for 6 cycles)	780 mg/m ²	Hand and foot baths of Huzhou decoction (30 minutes bid for 2 weeks, n = 45)	Vitamin B12 (0.5 mg tid for 3 weeks, n = 45)	1. NCI-CTC sensory grade 1.1 Grade \geq 1 1.2 Grade \geq 2 1.2 Grade \geq 3 2. MNCV 2.1 Median nerve 2.2 Fibular nerve 3. SNCV	1.1 P < .01 1.2 P < .01 1.3 P > .05 2.1 P < .01 2.2 P < .01 3.1 P < .01 3.2 P < .01	NR
Wang (2015)	120 (0)	52 (N/A)	61:59 (49%)	Colorectal cancer: 120	mFOLFOX 6 (85mg/m ² , 2 wk/cycle for 8 cycles)	680 mg/m ²	(a) Hand and foot baths of Huangqiuzhiwuwu decoction (30 minutes, 35°C-40°C, qd for 1 week, n = 30) (b) Hand and foot baths of Huangqiuzhiwuwu decoction (30 minutes, 35°C-40°C, qd for 1 week) + Ca-Mg infusion (n = 30)	(c) No additional Tx (n = 30) (d) Ca-Mg infusion (n = 30)	1. Levi's grade (a vs c) 1.1 Grade \geq 1 1.2 Grade \geq 2 1.2 Grade \geq 3 2. Levi's grade (a vs d) 2.1 Grade \geq 1 2.2 Grade \geq 2 2.3 Grade \geq 3 3. Levi's grade (b vs d) 3.1 Grade \geq 1 3.2 Grade \geq 2 3.3 Grade \geq 3	1.1 P > .05 1.2 P < .05 1.3 P > .05 2.1 P > .05 2.2 P < .05 2.3 P > .05 3.1 P > .05 3.2 P < .01 3.3 P > .05	NR
Huang (2010)	60 (0)	47 (34-72)	17:43 (72%)	Colorectal cancer: 60	FOLFOX (85-135 mg/m ² , 2 wk/cycle for 4 cycles)	340-540 mg/m ²	Hand and foot baths of Huangqiuzhiwuwu decoction (30 minutes, 38°C -42°C, bid for 5 days, n = 30)	No additional Tx. (n = 30)	1. Levi's grade 1.1 Grade \geq 1 1.2 Grade \geq 2 1.2 Grade \geq 3 2. MNCV 2.1 Median nerve 2.2 Fibular nerve 3. SNCV	1.1 P < .01 1.2 P < .05 1.3 P > .05 2.1 P < .05 2.2 P < .05 3.1 P < .05 3.2 P < .05	NR
Zhang (2017)	44 (2)	63 (39-75)	16:28 (67%)	Gastric cancer: 7; colorectal cancer: 37	FOLFOX4 or FOLFOX 6 (85 mg/m ² , 2 wk/cycle for 12 cycles)	1020 mg/m ²	Hand and foot baths of Huangwuteng decoction (30 minutes, 38°C-45°C, bid during CTx) + Vitamin B12 (0.5 mg tid for 1 week, n = 22)	Vitamin B12 (0.5 mg tid for 1 week, n = 20)	1. NCI-CTC sensory grade 1.1 Grade \geq 1 1.2 Grade \geq 2 1.2 Grade \geq 3 2. SNCV (median nerve) 3. ADL score 4. Cumulative OXA dose to TTN (grade \geq 1)	1.1 P < .05 1.2 P < .05 1.3 P > .05 2. P < .01 3. P < .05 4. P < .01	NR

(continued)

Table 1. (continued)

First Author (Year)	Sample Size (Dropouts)	Mean Age (Median range)	Women:Men (Percentage Men)	Type of Cancer	Common Treatment in Both Groups (Regimen)	Cumulative Oxaliplatin Dose	Intervention Group (Regimen, Participants)	Control Group (Regimen, Participants)	Primary and Secondary Outcomes	Intergroup Differences at the End	Follow-up
Yang (2015)	72 (3)	64 (54-72)	31:38 (55%)	Gastric cancer: 29; colorectal cancer: 40	FOLFOLX4 (85 mg/m ² , 2 wk/cycle for 6 cycles)	510 mg/m ²	Hand and foot baths of Wenyanghuoetongluo decoction (30 minutes, 40°C, bid for 7 days, n = 35)	No additional Tx (n = 34)	1. Levi's grade 1.1 Grade ≥ 1 1.2 Grade ≥ 2 1.3 Grade ≥ 3 2. QoL-KPS	1.1 $P < .05$ 1.2 $P < .01$ 1.3 $P > .05$ 2. $P < .05$	NR
Yuan (2015)	60 (5)	58 (49-64)	26:29 (53%)	Gastric cancer: 15; colorectal cancer: 40	FOLFOLX4 85 mg/m ² or FOLFOLX 6 100 mg/m ² (2 wk/cycle for 4 cycles); XELOX 130 mg/m ² or L-OHP+51 100 mg/m ² (3 wk/cycle for 4 cycles)	340-520 mg/m ²	Hand and foot baths of Huoxuetongling decoction (30 minutes, 38°C-41°C, bid during CTx, n = 27)	Warm water for hand and foot baths (30 minutes bid during CTx, n = 28)	1. WHO grade 1.1 Grade ≥ 1 1.2 Grade ≥ 2 1.3 Grade ≥ 3 2. Cumulative OXA dose to TTN (grade ≥ 2) 3. Adverse events	1.1 $P = .01$ 1.2 $P < .05$ 1.3 $P > .05$ 2. $P > .05$ 3. $P > .05$	NR
Wang (2014)	70 (3)	55 (45-64)	31:36 (54%)	Gastric cancer: 41; colorectal cancer: 26	FOLFOLX 6 (135mg/m ² , 2 wk/cycle for 6 cycles)	810 mg/m ²	Hand and foot baths of Wenyanghuoetong decoction (40 minutes, 38°C, qd for 5 days, n = 34)	No additional Tx (n = 33)	1. Levi's grade 1.1 Grade ≥ 1 1.2 Grade ≥ 2 1.3 Grade ≥ 3 2. Adverse events	1.1 $P < .01$ 1.2 $P < .05$ 1.3 $P > .05$ 2. $P > .05$	NR
Deng (2014)	128 (23)	60 (48-71)	48:57 (54%)	Gastric cancer: 23; colorectal cancer: 82	FOLFOLX4 85 mg/m ² or FOLFOLX 6 100 mg/m ² (2 wk/cycle for 8 cycles); XELOX 130 mg/m ² or L-OHP+51 100 mg/m ² (3 wk/cycle for 8 cycles)	680-1040 mg/m ²	Hand and foot baths of Yangxuewenjingtongluo decoction (20 minutes, 38°C-42°C, bid for CTx, n = 54)	No additional Tx (n = 51)	1 WHO grade 1.1 Grade ≥ 1 1.2 Grade ≥ 2 1.3 Grade ≥ 3 2. TCSS neuropathy score 3. Cumulative OXA dose to TTN (grade ≥ 2) 4. Adverse events	1.1 $P < .05$ 1.2 $P < .01$ 1.3 $P > .05$ 2. $P < .05$ 3. $P > .05$ 4. $P > .05$	NR
Li (2010)	90 (0)	51 (39-63)	41:49 (54%)	Gastric cancer: 26; esophageal cancer: 11; colorectal cancer: 53	FOLFOLX4 (85 mg/m ² , 2 wk/cycle for 6 cycles)	510 mg/m ²	Hand and foot baths of Wenyanghuoetong decoction (20 minutes, 38°C-40°C, qd during CTx, n = 45)	No additional Tx (n = 45)	1. Levi's grade 1.1 Grade ≥ 1 1.2 Grade ≥ 2 1.3 Grade ≥ 3	1.1 $P < .01$ 1.2 $P = .01$ 1.3 $P > .05$	NR

Abbreviations: OIPN, OXA-induced peripheral neurotoxicity; XELOX, oxaliplatin + capecitabine; NCI-CTC, National Cancer Institute Common Terminology Criteria for Adverse Events Sensory Neuropathy Scale; MNCV, motor nerve conduction velocity; SNCV, sensory nerve conduction velocity; FOLFOLX, oxaliplatin + 5-fluorouracil + calcium folinate; ADL, Activities of Daily Living; OXA, oxaliplatin; TTN, time to neuropathy; CTx, chemotherapy treatment; QoL, quality of life; KPS, Karnofsky Performance Score; WHO, World Health Organization; L-OHP+51, Oxaliplatin + Tegafur Gimeracil Oteracil Potassium Capsule; TCSS, Toronto Clinical Scoring System.




Figure 1. Flowchart of the selection of publications included in the meta-analysis.

risk of included studies bias was assessed in accordance with the guidelines of the Cochrane Collaboration.²³

Results

Literature Search and Characteristics of Included Studies

A total of 961 potentially relevant references were identified. After reading the titles and abstracts, 62 duplicate articles were excluded and 850 studies that did not meet the eligibility criteria were removed. A total of 49 references were retrieved for further assessment. After full-text reviews, 9 trials were included in the analysis (Figure 1).²⁴⁻

³² All the included trials were conducted in China and published from 2010 to 2017. All trials used random number tables for randomization. However, inadequate allocation

concealment as well as lack of blinding of participants and personnel was identified as high risk of bias for all trials (Figure 2). Five trials reported dropouts.²⁷⁻³¹ One implemented an intention-to-treat analysis,²⁷ and one with a more than 20% drop-out rate in the control group was assessed to be at a high risk for bias.²⁸ For 3 trials, it was assessed that the proportion of missing outcomes was not sufficient to have a clinically relevant impact on the intervention effect estimate. Overall, most studies reported prespecified outcomes, but only 1 study that did not report expected outcomes was deemed to be at high risk of bias.²⁸

Participants

In total, 700 participants with chemotherapy were included in these 9 trials, of whom 352 received Chinese herbal hand and foot baths (CHM group) and 348 were in one of the control

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Chen 2017	+	-	-	?	+	+	-
Deng 2014	+	-	-	?	+	+	?
Huang 2010	+	-	-	?	+	+	-
Li 2010	+	-	-	?	+	+	-
Wang 2014	+	-	-	?	+	+	?
Wang 2015	+	-	-	?	+	+	-
Yang 2015	+	-	-	?	+	-	?
Yuan 2015	+	-	-	?	+	+	?
Zhang 2017	+	-	-	?	+	+	-

Figure 2. Summary of risk of bias (“+,” low risk of bias; “?,” unclear risk of bias; “-,” high risk of bias).

groups. The average size of the trials was 82 participants, ranging from 44 to 128 per trial. Four trials enrolled both inpatients and clinic outpatients (n = 317 patients, 45.3%).²⁹⁻³² One study recruited solely from inpatients.²⁸ The remaining 4 trials did not specify the clinical setting (n = 314 patients, 44.9%).²⁴⁻²⁷ All trials included both adult male and female patients, with 55% of participants (n = 386) being male. All participants were diagnosed with gastrointestinal cancer. Types of cancer included colorectal cancer (n = 499 patients, 71.3%), gastric cancer (n = 190 patients, 27.1%), and esophageal cancers (n = 11, patients, 1.6%). Cumulative OXA dose varied from 340 to 1040 mg/m², with a mean value at 671 mg/m².

Interventions and Controls

More than 67% (6/9) of the studies compared Chinese herbal hand and foot baths with no intervention. Of the 6 trials, one reported 3 study arms: (1) no additional intervention, (2) Ca/Mg infusion therapy, and (3) herbal bath plus Ca/Mg infusion therapy. Two additional studies compared CHM with mecobalamin, and CHM plus mecobalamin with mecobalamin alone. One study used warm water baths as the control arm. No study included specifically designed placebo herbal baths.

The active herbal formulations were varied. Nine formulae with a total of 34 herbal ingredients were investigated; 18 herbs were identified as the most frequently tested (Tables 2 and 3). Six studies reported full compositions of the herbal formulae. In contrast, 3 studies did not report all ingredients used.^{28,29,31} Seven studies mentioned the full dosages of herbal ingredients, whereas dosage information was missing from the remaining 2 studies.^{29,31} None of the studies reported any laboratory testing of the herbal ingredients for quality control or standardization. Only 1 trial cited relevant pharmacological bases for the intervention.²⁵ All trials administered raw herbs externally in the form of decoctions. The lengths of trial periods varied from 4 to 12 chemocycles (8-24 weeks). Six cycles were used in 4 studies, 4 cycles in 3 studies, and 8 cycles in 3 studies, and 1 study used a 12-cycle intervention. The included studies were characterized by variation in formulation, dosage administration, and duration of treatments.

Outcome Measurements

All trials assessed the incidence of OXA-induced peripheral neuropathy as the primary outcome. The majority of trials (5/9) used Levi grading of chemotherapy-induced peripheral neuropathy.^{25,26,28,30,32} Two trials used the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria of chemotherapy-induced peripheral neuropathy,^{24,27} and 2 trials used WHO criteria of chemotherapy-induced peripheral neuropathy.^{29,31} Two trials reported on performance/functionality outcomes.^{28,29} Three trials also reported intervention-related adverse events,^{29,31} and 2 trials reported additional chemotherapy-induced adverse events.^{29,31} Three trials reported on sensory NCV (SNCV),^{24,26,27} and 2 of them also reported on motor NCV (MNCV).^{24,26}

Effects of Interventions

Primary Outcome

Incidence of Levi grade ≥ 1 total cumulative neurotoxicity. All 9 trials reported incidence of total cumulative neurotoxicity (Levi grade scores from 1 to 4). Six trials (n = 451 patients) compared CHM with no intervention.^{25,26,28,30-32} For these 6 studies, a difference was found between the 2 groups in favor of CHM in reducing OIPN occurrence (OR = 0.22; 95% CI = 0.11 to 0.45; P < .01). There was moderate heterogeneity between studies (P = 52%; Figure 3). In the subgroup analyses, in 4 trials (n = 287 patients), this outcome was in favor of CHM after 4 cycles of chemotherapy (OR = 0.21, 95% CI = 0.13 to 0.37, P < .01; P = 24%).^{26,28,30,32} In 3 trials (n = 226 patients), CHM was superior to no intervention after 6 cycles of chemotherapy (OR = 0.15, 95% CI = 0.08 to 0.30, P < .01;

Table 2. Frequency of Use of the Herbs in External Chinese Herbal Formulas for OIPN.

Pinyin Name	Pharmaceutical Name	Counts (Frequency)	Citations (First Author; Year)
Huang Qi	Radix Astragali	7 (77.8%)	Chen 2017; Wang 2015; Huang 2010; Zhang 2017; Yang 2015; Yuan 2015; Deng 2014
Ji Xue Teng	Caulis Spatholobi	6 (66.7%)	Chen 2017; Wang 2015; Zhang 2017; Yang 2015; Yuan 2015; Deng 2014
Gui Zhi	Ramulus Cinnamomi	6 (66.7%)	Chen 2017; Wang 2015; Huang 2010; Zhang 2017; Wang 2014; Li 2010
Hong Hua	Flos Carthami	6 (66.7%)	Chen 2017; Wang 2015; Yang 2015; Yuan 2015; Wang 2014; Deng 2014
Bai Shao	Radix Paeoniae Alba	4 (44.4%)	Chen 2017; Wang 2015; Huang 2010; Wang 2014
Dang Gui	Radix Angelicae Sinesis	4 (44.4%)	Chen 2017; Zhang 2017; Yang 2015; Deng 2014
Fu Zi	Radix Aconiti Lateralis	4 (44.4%)	Wang 2015; Yang 2015; Wang 2014; Li 2010
Tao Ren	Semen Persicae	3 (33.3%)	Chen 2017; Wang 2015; Yuan 2015
Chuan Wu	Radix Aconiti	3 (33.3%)	Zhang 2017; Yang 2015; Deng 2014
Ai Ye	Folium Artemisiae Argyi	2 (22.2%)	Chen 2017; Yang 2015
Wei Ling Xian	Radix et Rhizoma Clematidis	2 (22.2%)	Chen 2017; Yuan 2015
Dan Shen	Radix et Rhizoma Salviae Miltiorrhizae	2 (22.2%)	Chen 2017; Wang 2015
Niu Xi	Radix Cyathulae	2 (22.2%)	Chen 2017; Zhang 2017
Sheng Jiang	Rhizoma Zingiberis Recens	2 (22.2%)	Wang 2015; Huang 2010
Da Zao	Fructus Jujubae	2 (22.2%)	Wang 2015; Huang 2010
Chuan Xiong	Radix Chuanxiong	2 (22.2%)	Zhang 2017; Wang 2014
Gan Cao	Radix et Rhizoma Glycyrrhizae	2 (22.2%)	Wang 2014; Li 2010
Cao Wu	Radix Aconiti Kusnezoffii	2 (22.2%)	Zhang 2017; Yang 2015

Abbreviation: OIPN, oxaliplatin-induced peripheral neurotoxicity.

$P = 0\%$).^{28,30,32} In 2 other studies ($n = 165$ patients), CHM had significant positive results after 8 treatment cycles (OR = 0.49, 95% CI = 0.24 to 1.01, $P = .05$; $P^2 = 0\%$; Figure 4).^{25,31} CHM also showed a reduction in OIPN incidence compared with warm water bath ($n = 55$ patients; OR = 0.20, 95% CI = 0.06 to 0.69, $P = .01$)²⁸ or mecobalamin ($n = 90$ patients; OR = 0.18, 95% CI = 0.07 to 0.45, $P < .01$).²⁴ One trial ($n = 44$ patients)²⁷ compared CHM plus mecobalamin to mecobalamin, demonstrating a difference in favor of CHM plus mecobalamin after 8 and 12 treatment cycles (OR = 0.02, 95% CI = 0.00 to 0.11, $P < .01$, and OR = 0.23, 95% CI = 0.05 to 1.01, $P = .05$, respectively). One trial ($n = 60$ patients) reported no statistically significant difference in either CHM versus Ca/Mg infusion (OR = 1.00; 95% CI = 0.28 to 3.54; $P > .05$) or CHM plus Ca/Mg infusion versus Ca/Mg infusion alone (OR = 0.50; 95% CI = 0.15 to 1.62; $P > .05$).²⁵

Incidence of Levi grade ≥ 2 cumulative neurotoxicity. Nine trials reported that CHM had an advantage in reducing the Levi grade ≥ 2 of cumulative neurotoxicity. Five trials ($n = 346$ patients) reported that the incidence of grade ≥ 2 cumulative neurotoxicity in the CHM group was lower than that in the nonintervention control group (OR = 0.19, 95% CI = 0.11 to 0.32, $P < .01$; Figure 5).^{25,26,28,30,32} This result

was consistently reported at different stages of treatment: in 4 trials ($n = 287$ patients) after 4 cycles (OR = 0.20, 95% CI = 0.11 to 0.39, $P < .01$; $P^2 = 0\%$); in 3 trials ($n = 226$ patients) after 6 cycles (OR = 0.15, 95% CI = 0.07 to 0.30, $P < .01$; $P^2 = 0\%$); and in 1 trial ($n = 60$ patients) after 8 cycles (OR = 0.33, 95% CI = 0.12 to 0.96, $P < .05$; Figure 6). Compared with Ca/Mg infusion, 1 study ($n = 60$ patients)²⁵ reported that the grade ≥ 2 cumulative neurotoxicity was significantly decreased in the CHM (OR = 0.33, 95% CI = 0.12 to 0.96, $P < .05$) and the CHM plus Ca/Mg infusion groups (OR = 0.05; 95% CI = 0.01 to 0.24; $P < .01$). Compared with mecobalamin, 1 trial ($n = 90$ patients)²⁴ reported this outcome in favor of CHM (OR = 0.19; 95% CI = 0.06 to 0.57; $P < .01$) and another trial ($n = 44$ patients)²⁷ was in favor of CHM plus mecobalamin (OR = 0.22; 95% CI = 0.06 to 0.87; $P < .05$). Compared with a warm water bath control, 1 study ($n = 55$ patients)²⁹ reported a reduced incidence of grade ≥ 2 cumulative neurotoxicity in the CHM (OR = 0.19; 95% CI = 0.05 to 0.80; $P < .05$).

Incidence of Levi grade ≥ 3 cumulative neurotoxicity. Five trials ($n = 346$ patients) examined the effect between CHM and no intervention on the Levi grade ≥ 3 , with a significant difference in favor of CHM (OR = 0.19, 95% CI = 0.07 to 0.52, $P < .01$; $P^2 = 0\%$; Figure 7).^{25,26,28,30,32} In the relevant

Table 3. Composition of the External Chinese Herbal Formulas for OIPN.

First Author (Year)	Composition (Daily Dosage)
Chen (2017)	<i>Huzhou decoction</i> : Radix Astragalii (Huang Qi) 40 g, Ramulus Cinnamomi (Gui Zhi) 40 g, Folium Artemisiae Argyi (Ai Ye) 12 g, Caulis Spatholobi (Ji Xue Teng) 30 g, Radix et Rhizoma Clematidis (Wei Ling Xian) 15 g, Radix et Rhizoma Salviae Miltiorrhizae (Dan Shen) 15 g, Radix Paeoniae Alba (Bai Shao) 12 g, Radix Angelicae Sinesis (Dang Gui) 12 g, Radix Cyathulae (Niu Xi) 15 g, Semen Persicae (Tao Ren) 12 g, Flos Carthami (Hong Hua) 10 g, Radix Angelicae Pubescentis (Du Huo) 10 g, Rhizoma et Radix Notopterygii (Qiang Huo) 10 g
Wang (2015)	<i>Huang Qi Gui Zhi Wu decoction</i> : Radix Astragalii (Huang Qi) 45 g, Radix Paeoniae Alba (Bai Shao) 15 g, Ramulus Cinnamomi (Gui Zhi) 45 g, Rhizoma Zingiberis Recens (Sheng Jiang) 20 g, Fructus Jujubae (Da Zao) 10 g, Caulis Spatholobi (Ji Xue Teng) 45 g, Semen Persicae (Tao Ren) 10 g, Flos Carthami (Hong Hua) 10 g, Radix et Rhizoma Salviae Miltiorrhizae (Dan Shen) 10 g, Radix Aconiti Lateralis (Fu Zi) 10 g
Huang (2010)	<i>Huang Qi Gui Zhi Wu decoction</i> : Radix Astragalii (Huang Qi) 100 g, Radix Paeoniae Alba (Bai Shao) 30 g, Ramulus Cinnamomi (Gui Zhi) 20 g, Rhizoma Zingiberis Recens (Sheng Jiang) 10 g, Fructus Jujubae (Da Zao) 10 g
Zhang (2017)	<i>Huangwuteng topical wash decoction</i> : Radix Astragalii (Huang Qi) 30 g, Caulis Spatholobi (Ji Xue Teng) 30 g, Caulis Trachelospermi (Luo Shi Teng) 30 g, Radix Tinosporae (Jin Guo Lan) 30 g, Ramulus Mori (Sang Zhi) 30 g, Radix Angelicae Sinesis (Dang Gui) 30 g, Ramulus Cinnamomi (Gui Zhi) 10 g, Radix Gentianae Macrophyllae (Qin Jiao) 10 g, Radix Cyathulae (Niu Xi) 10 g, Radix Chuanxiong (Chuan Xiong) 20 g, Cortex Phellodendri Chinensis (Huang Bo) 15 g, Herba Taraxaci (Pu Gong Ying) 30 g, Radix Aconiti (Chuan Wu) 20 g, Radix Aconiti Kusnezoffii (Cao Wu) 20 g
Yang (2015)	<i>Wenyangtongluo decoction</i> : Radix Astragalii (Huang Qi) 50 g, Radix Aconiti Lateralis (Fu Zi) 15 g, Radix Angelicae Sinesis (Dang Gui) 10 g, Flos Carthami (Hong Hua) 10 g, Caulis Polygoni Multiflori (Shou Wu Teng) 15 g, Caulis Spatholobi (Ji Xue Teng) 15 g, Radix Aconiti (Chuan Wu) 10 g, Radix Aconiti Kusnezoffii (Cao Wu) 10 g, Pheretima (Di Long) 15 g, Hirudo (Shui Zhi) 6 g, Fructus Liquidambaris (Lu Tong) 15 g, Folium Artemisiae Argyi (Ai Ye) 15 g, etc
Yuan (2015)	<i>Huoxuetongjing decoction</i> : Radix Astragalii (Huang Qi), Semen Persicae (Tao Ren), Flos Carthami (Hong Hua), Radix Paeoniae Rubra (Chi Shao), Rhizoma Curcumae (E Zhu), Radix et Rhizoma Clematidis (Wei Ling Xian), Herba Erodii (Lao Guan Cao), Caulis Spatholobi (Ji Xue Teng), etc (dosage not available)
Wang (2014)	<i>Wengjinguoxue decoction</i> : Ramulus Cinnamomi (Gui Zhi) 12 g, Herba Ephedrae (Ma Huang) 6 g, Radix Paeoniae Alba (Bai Shao) 12 g, Flos Carthami (Hong Hua) 9 g, Radix Chuanxiong (Chuan Xiong) 30 g, Radix Aconiti Lateralis (Fu Zi) 6 g, Radix et Rhizoma Glycyrrhizae (Gan Cao) 6 g
Deng (2014)	<i>Yangxuewenjingtongluo decoction</i> : Radix Astragalii (Huang Qi), Radix Angelicae Sinesis (Dang Gui), Flos Carthami (Hong Hua), Radix Aconiti (Chuan Wu), Caulis Spatholobi (Ji Xue Teng), etc (dosage not available)
Li (2010)	<i>Wenjingtongluo decoction</i> : Radix Aconiti Lateralis (Fu Zi) 40 g, Ramulus Cinnamomi (Gui Zhi) 60 g, Radix et Rhizoma Glycyrrhizae (Gan Cao) 20 g, Herba Lycopodii (Shen Jin Cao) 60 g

Abbreviation: OIPN, oxaliplatin-induced peripheral neurotoxicity.

subgroup analyses, 4 trials ($n = 287$ patients), found in favor of CHM after 4 cycles (OR = 0.20, 95% CI = 0.06 to 0.70, $P = .01$; $P = 0\%$).^{26,28,30,32} In 3 trials ($n = 226$ patients), a reduction in the neurotoxicity grade was reported for CHM after 6 cycles (OR = 0.16, 95% CI = 0.05 to 0.57, $P < .01$; $P = 0\%$).^{28,30,32} No significant differences were observed after 8 cycles ($n = 60$ patients; OR = 0.19, 95% CI = 0.01 to 4.06, $P > .05$; $P = 0\%$; Figure 8).²⁵ However, 4 other trials found no statistical difference in grade ≥ 3 cumulative neurotoxicity incidence between groups. This included CHM versus mecobalamin ($n = 90$ patients; OR = 0.22, 95% CI = 0.04 to 1.08, $P > .05$),²⁴ CHM plus mecobalamin versus mecobalamin ($n = 44$ patients; OR = 0.18, 95% CI = 0.01 to 4.02, $P > .05$),²⁷ CHM versus warm water bath ($n = 55$ patients; OR = 0.19, 95% CI = 0.01 to 4.21, $P > .05$),²⁹ CHM versus Ca/Mg infusion ($n = 60$ patients; OR = 0.32, 95% CI = 0.01 to 8.24, $P > .05$),²⁵ and CHM plus Ca/Mg infusion versus Ca/Mg infusion ($n = 60$ patients; OR = 0.32, 95% CI = 0.01 to 8.24, $P > .05$).²⁵

Nerve conduction velocity. There were significant differences in SNCV of both the median nerve and fibular nerve in favor of CHM treatment compared with no intervention²⁶ ($n = 60$ patients; MD 4.92 m/s, 95% CI = 2.92 to 6.92, $P < .01$; MD = 5.52 m/s, 95% CI = 4.08 to 6.96, $P < .01$) and CHM compared with mecobalamin²⁴ ($n = 90$ patients; MD = 6.22 m/s, 95% CI = 4.60 to 7.84, $P < .01$; MD = 5.09 m/s, 95% CI = 3.62 to 6.56, $p < .01$) studies. Compared with mecobalamin, 1 study ($n = 44$ patients)²⁷ reported improved SNCV in CHM plus mecobalamin after 8 (MD = 4.54 m/s, 95% CI = 0.89 to 8.19, $P = .01$) and 12 cycles of chemotherapy ($n = 44$ patients; MD = 6.77 m/s, 95% CI = 2.33 to 11.21, $P < .01$) but not after 4 cycles ($n = 44$ patients; MD = 1.77 m/s, 95% CI = -1.44 to 4.98, $P > .05$). CHM plus mecobalamin treatment also improved MNCV in the median and fibular nerves after both 8 and 12 cycles compared with mecobalamin alone²⁴ ($n = 90$ patients; MD = 6.88 m/s, 95% CI = 5.06 to 8.70, $P < .01$; MD = 8.20 m/s, 95% CI = 6.83 to 9.57, $P < .01$). There




Figure 3. Comparison of CHM and no intervention by total cumulative neurotoxicity at the end of the study. Abbreviation: CHM, Chinese herbal medicine.




Figure 4. Comparison of CHM and no intervention by total cumulative neurotoxicity after 4/6/8 cycles of chemotherapy. Abbreviation: CHM, Chinese herbal medicine; OXA, oxaliplatin.

was no statistical difference of median motor nerve conduction between CHM and no intervention (n = 60 patients; MD = -1.22 m/s, 95% CI = -2.80 to 0.36, P > .05).²⁶

Toronto Clinical Neuropathy Score. One trial (n = 105 patients) using the Toronto Clinical Neuropathy Score showed that clinical neuropathy symptoms and signs were significantly improved in the CHM group compared with

no intervention (MD = -2.70; 95% CI = -3.65 to -1.75; P < .01).³¹

Secondary Outcomes

Safety outcomes. Three studies reported on safety outcomes.²⁹⁻³¹ There was no significant difference in the incidence of intervention-related adverse events in the CHM compared with no intervention groups (n = 175 patients;




Figure 5. Comparison of CHM and no intervention groups by Levi grade ≥ 2 cumulative neurotoxicity at the end of the study. Abbreviation: CHM, Chinese herbal medicine.




Figure 6. Comparison of CHM and no intervention groups by Levi grade ≥ 2 cumulative neurotoxicity after 4/6/8 cycles of chemotherapy. Abbreviation: CHM, Chinese herbal medicine.

OR = 6.11, 95% CI = 0.72 to 51.77, $P > .05$; Figure 9)^{30,31} or warm water bath (n = 55 patients; OR = 3.23, 95% CI = 0.13 to 82.71, $P > .05$).²⁹

Performance/Functionality measures. One trial (n = 79 patients) reported that CHM had a statistically significant effect on the Karnofsky Performance Score (KPS) compared with no intervention (MD = 2.79; 95% CI = 0.28 to 5.30; $P < .05$).²⁸ Another trial (n = 44 patients) reported

statistically improved Activities of Daily Living (ADL) in favor of CHM plus mecobalamin compared with mecobalamin alone after 8 (OR = 14.00; 95% CI = 6.39 to 21.61; $P < .01$) and 12 cycles of chemotherapy (OR = 10.77; 95% CI = 1.88 to 19.66; $P < .05$).²⁷

Time to neuropathy. Three studies assessed time to neuropathy as an outcome.^{27,29,31} One study (n = 44 patients) reported that CHM plus mecobalamin significantly increased




Figure 7. Comparison of CHM and no intervention groups by Levi grade ≥3 cumulative neurotoxicity at end of the study. Abbreviation: CHM, Chinese herbal medicine.




Figure 8. Comparison of CHM and no intervention groups by Levi grade ≥3 cumulative neurotoxicity after 4/6/8 cycles OXA. Abbreviations: CHM, Chinese herbal medicine; OXA, oxalipatin.

the time to NCI-CTC ≥1 neuropathy (OR = 144.59 mg; 95% CI = 84.17 to 205.01; *P* < .01) and the time to NCI-CTC ≥2 neuropathy (OR = 106.25 mg; 95% CI = 56.32 to 156.18; *P* < .01).²⁷ CHM versus warm water bath (n = 55 patients; MD = 75.20 mg, 95% CI = -56.70 to 207.10, *P* > .05)²⁹ or CHM versus no intervention (n = 105 patients; MD 83.20 mg, 95% CI = -17.58 to 183.98, *P* > .05)³¹ demonstrated no significant differences in time to onset of WHO grade ≥2 neuropathy.

Discussion

This review aimed to explore the potential effectiveness and safety of externally applied CHM in chemotherapy-induced peripheral neuropathy. Nine studies were eligible for inclusion in our review.

The incidence of neuropathy following treatment cycles of OXA can vary.³³ From the primary outcome reported in 6 studies, it was found that external use of CHM could delay the incidence of cumulative OIPN (grade ≥ 1, 2, 3)




Figure 9. Comparison of CHM and no intervention group by intervention-related adverse events at the end of the study. Abbreviation: CHM, Chinese herbal medicine.

compared with no intervention and other controls. Most studies reported these changes using the Levi Scale with end points that were variable across trials. Only 1 study utilized the Toronto Clinical Neuropathy Score.

Findings also suggest that CHM may improve QoL and increase SNCV, although data from these studies could not be pooled. There was controversy regarding the efficacy of enhancing SNCV from inconsistent data because of various chemotherapy cycles. From this review, CHM did not increase the MNCV.

The above outcome measures have been shown to detect occurrences in neuropathy over time with the administration of OXA. However, the sensitivity of either measure to detect small or moderate differences in the OIPN incidence and severity is uncertain. For example, the NCI-CTCAE was not recognized as an appropriate primary outcome measure from the latest released recommendations.³³ Thus, in the design of future studies, incorporating neurophysiological measurements, clinical examination with good reliability and interrater reliability (eg, Total Neuropathy Score clinical version (TNSc), and patient-reported outcome measurements should be considered.^{33,34}

Safety

In general, Chinese herbal hand and foot baths were well tolerated based on the reported clinical adverse effects. There was no difference in the incidence of adverse events between CHM versus no intervention and CHM versus warm water bath. Adverse events were usually rare and reported to be mild. These adverse events included the development of a skin rash and irritation after the baths. There were no reports of systemic adverse events in these patients.

How the Intervention Might Work

Herbal ingredients prescribed for OIPN often contain active compounds promoting blood circulation. In vivo, Huangqiguizhiwu decoction has been shown to relieve pain as well as ameliorate sciatic NCV in rats with

chemotherapy-induced peripheral neuropathy.³⁵ AC591, a standardized extract from this herbal decoction, reduced OXA-induced cold hyperalgesia, mechanical allodynia, and morphological damage of the dorsal root ganglion.³⁶ Similarly, in other in vitro and in vivo studies, Radix Astragali extract, Radix Paeoniae alba extract, puerarin from *Pueraria lobate*, and Tanshinone IIA from *Salvia miltiorrhiza* were all observed to be potential nerve growth-promoting factors in peripheral nerve regeneration.³⁷⁻⁴² In particular, Astragali Radix reduced OXA-induced cold hypersensitivity, completely blocked the onset of the proalodynia effect, and protected against neurodamage-induced pain in OXA-treated rats.^{39,40} However, the applicability of those animal studies to the use of hand and foot baths is not clear.⁴³ Because of the characteristic of OIPN, the direct topical application of herbal medicine could be an effective practice.^{17,18}

Limitations of the Review

We only reviewed studies with patients who had not yet demonstrated any neuropathy symptoms, focusing on appraisals of the preventive efficacy of hand and foot baths. This excluded a considerable number of trials of patients with preexisting neuropathy. Although the search strategy was comprehensive, unpublished studies and those published in languages other than English and Chinese could have been unintentionally missed. All the participants were recruited from Chinese populations; so results should be interpreted with caution when applied to other ethnic groups. Publication bias cannot be excluded. Furthermore, the quality of the evidence was potentially affected when flaws in design led to high risk of bias in allocation, blinding, and selective reporting issues. Absence of multicenter or large-scale RCTs, sample size calculation, and follow-up impeded access to (long-term) reliable outcomes. Finally, the intervention group method described included the following: (1) soaking hands and feet in the herbal solution; (2) soaking between 20 and 40 minutes; (3) water temperature between 35°C and 45°C; (4) soaking once or twice a day for 5 to 21 days; and (5) beginning on the same day of

initial OXA infusion or 1 day before. However, no consensus exists regarding which of these interventions is the best to address the efficacy. The review was compromised because various herbal combinations (or formula solutions) were used, and the reporting of CHM formulas (eg, herbal preparations, production, safety assessment) was inadequate.⁴⁴ Consistent inclusion of a specific OIPN intervention in future RCTs would help standardize Chinese herbal hand and foot baths and facilitate comparison across studies. Future network meta-analysis can also be conducted to compare the preventive efficacy between the different herbal formulations (or combinations).

Conclusion

To the best of the authors' knowledge, this is the first meta-analysis that focuses on external use of CHM (hand and foot baths) for the prevention of cumulative OXA-related neurotoxicity. CHM tends to decrease the incidence of OXA-induced cumulative neurotoxicity. Importantly, no adverse events were reported significantly altering the efficacy of chemotherapy, thus enhancing patients' tolerance to OXA treatment. However, all the included studies suffered from numerous methodological shortcomings and were, therefore, assessed to be at high risk of bias. Further high-quality prospective randomized data taking into account the characteristics of traditional Chinese medicine should be conducted to substantiate findings of the studies in this review.

Appendix

Search strategies for MEDLINE and CNKI.

MEDLINE (via Ovid) Search Strategy

- #1. Exp Organoplatinum/
- #2. ((oxaliplatin) or Eloxaliplatin or OXALIPLATIN or L-OHP or OHP or (platinum compounds)).mp
- #3. #1 or #2
- #4. Exp Peripheral Nervous System Disease/
- #5. (neuralgia or paresthesia or hyperalgesia or (chemotherapy induced peripheral neuropathy) or CIPN or (peripheral neuropathy) or Polyneuropath* or (chemotherapy induced neurotoxicity) or (cancer neuropathic pain)).mp.
- #6. #4 or #5
- #7. exp Drugs, Chinese herbal/
- #8. exp Herbal Medicine/
- #9. exp Plants, Medicinal/
- #10. exp Medicine, Chinese Traditional/
- #11. (traditional Chinese medicine or traditional Korean medicine or Traditional oriental medicine or Kampo medicine or alternative medicine or complementary

medicine or herb* or herbal* or decoction* or botanic* or galenical*).mp.

- #12. or/#7-#11
- #13. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or randomised.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.)
- #14. (external* or topical* or wash or bath or fumigat*).mp.
- #17. #3 and #6 and #12 and #13 and #14.

CNKI Search Strategy (in Chinese)

(oxaliplatin) and (peripheral neuropathy or secondary neuropathy or neurotoxicity) and (traditional Chinese medicine or integrative medicine or Oriental medicine or CHM or herbal medicine) and (externally used or external use or topical or topically or wash or bath or fumigation) and (random or control).

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work has supported by funding from the Western Sydney University Research Training Scheme (No. UWS18405473) and China Scholarship Council Higher Degree (Doctor of Philosophy) Program (No. CSC201506550006).

ORCID iD

Jie Hao,  <https://orcid.org/0000-0003-3450-9254>.

Supplemental Material

Supplemental material for this article is available online.

References

1. Sereno M, Gutiérrez-Gutiérrez G, Gómez-Raposo C, et al. Oxaliplatin induced-neuropathy in digestive tumors. *Crit Rev Oncol Hematol*. 2014;89:166-178.
2. Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. *Pain*. 2014;155:2461-2470.
3. Velasco R, Videla S, Villoria J, Ortiz E, Navarro X, Bruna J. Reliability and accuracy of quantitative sensory testing for oxaliplatin-induced neurotoxicity. *Acta Neurol Scand*. 2015;131:282-289.
4. Beijers AJ, Mols F, Tjan-Heijnen VC, Faber CG, van de Poll-Franse LV, Vreugdenhil G. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin

- administration: results from the population-based PROFILES registry. *Acta Oncol.* 2015;54:463-469.
5. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. *Cancer Treat Rev.* 2008;34:368-377.
 6. Lehy TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. *Muscle Nerve.* 2004;29:387-392.
 7. Briani C, Campagnolo M, Lucchetta M, et al. Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings. *Eur J Neurol.* 2013;20:188-192.
 8. Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors. *Support Care Cancer.* 2013;21:3307-3313.
 9. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. *J Clin Oncol.* 2013;31:2699-2707.
 10. Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. *Support Care Cancer.* 2014;22:2261-2269.
 11. Zedan AH, Hansen TF, Svenningsen AF, Vilholm OJ. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers. *Clin Colorectal Cancer.* 2014;13:73-80.
 12. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol.* 2014;32:1941-1967.
 13. Glimelius B, Manojlovic N, Pfeiffer P, et al. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmagofodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT). *Acta Oncol.* 2018;57:393-402.
 14. Piccolo J, Kolesar JM. Prevention and treatment of chemotherapy-induced peripheral neuropathy. *Am J Health Syst Pharm.* 2014;71:19-25.
 15. Yun H, Sun L, Mao JJ. Growth of integrative medicine at leading cancer centers between 2009 and 2016: a systematic analysis of NCI-designated comprehensive cancer center websites. *J Natl Cancer Inst Monogr.* 2017;2017(52). doi:10.1093/jncimonographs/lgx004
 16. Chung VC, Wu X, Hui EP, et al. Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses. *Sci Rep.* 2015;5:18111.
 17. Noh H, Yoon SW, Park B. A systematic review of herbal medicine for chemotherapy induced peripheral neuropathy. *Evid Based Complement Alternat Med.* 2018;2018:6194184.
 18. Yi J, Guochun L, Li L, et al. A systematic review and meta-analysis of Chinese herbal wash bath for preventing oxaliplatin induced peripheral neuropathy. *Chin Arch Tradit Chin Med.* 2017;2:6.
 19. Wei XC, Zhu LQ, Wang H, et al. Efficacy of traditional Chinese medicines in preventing oxaliplatin-induced peripheral neurotoxicity in cancer patients: a network meta-analysis. *Chin Herb Med.* 2017;9:161-168.
 20. Liu Y, May BH, Zhang AL, et al. Integrative herbal medicine for chemotherapy-induced peripheral neuropathy and hand-foot syndrome in colorectal cancer: a systematic review and meta-analysis. *Integr Cancer Ther.* 2019;18:1534735418817833.
 21. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ.* 2009;339:b2700.
 22. The Cochrane Collaboration. *Review Manager (RevMan)* [computer program]. Version 5.3. Copenhagen, Denmark: Nordic Cochrane Centre; 2014.
 23. Higgins JPT, Sally G. *Cochrane Handbook for Systematic Reviews of Interventions.* Version 5.1.0. London, England: The Cochrane Collaboration; 2011.
 24. Chen JF, Hy W. Clinical observation of "Huzhou decoction" in preventing and relieving chemotherapy induced peripheral neuropathy. *J China Chin Med Sci Technol.* 2017;24:2.
 25. Wang Q. Clinical study of the prevention and treatment effects of hand and foot baths of Huangqiguizhiwu decoction plus with Ca-Mg infusion on oxaliplatin induced peripheral neuropathy. *Mod J Integr Tradit Chin West Med.* 2015;24:3.
 26. Huang ZB, Huang ZM, Chen GQ, et al. Clinical study on external bath of "Huangqiguizhiwu Decoction" in relieving peripheral neurotoxicity induced by oxaliplatin. *Shanghai J Tradit Chin Med.* 2010;44:3.
 27. Zhang XQ. *Clinical Observation on Huang Wu Teng Lotion Prevention of Cold Dampness and Blood Stasis Type for Chronic Peripheral Nerve Toxicity Caused by Chemotherapy.* Zhengzhou, China: Henan University of Chinese Medicine; 2017.
 28. Yang Z. *Academic Thoughts and Clinical Experience From Yutang Wang and Clinical Study of the Prevention and Treatment Effects of Topical Wash Bath of "Wenyanghuoxuetongluo Decoction" on Oxaliplatin Induced Peripheral Neuropathy.* Beijing, China: Beijing University of Chinese Medicine; 2015.
 29. Yuan Y. *Clinical Study of the Prevention and Treatment Effects of Topical Wash Bath of Huoxuetongjing Decoction on Oxaliplatin Induced Peripheral Neuropathy.* Shenyang, China: Liaoning University of Traditional Chinese Medicine; 2015.
 30. Wang AM. *Clinical Observation of Chinese Herbal Medicine in Preventing and Relieving Oxaliplatin Induced Peripheral Neuropathy.* Hangzhou, China: Zhejiang University of Traditional Chinese Medicine; 2014.
 31. Deng C. *Clinical Research on the Prevention and Treatment of Neurotoxicity Induced by Oxaliplatin Through Nourishing Blood and Warming Channel for Dredging Collateral With Chinese Herbal Medicine Soaking.* Beijing, China: Capital Medical University; 2014.
 32. Li Y, Wu QL, Luo XL. Clinical nursing study of the prevention and treatment effects of Wenjingtongluo decoction on oxaliplatin induced peripheral neuropathy. *J Clin Med Eng.* 2010;17:2.
 33. Gewandter JS, Brell J, Cavaletti G, et al. Trial designs for chemotherapy-induced peripheral neuropathy prevention:

- ACTTION recommendations. *Neurology*. 2018;91:403-413.
34. Cavaletti G, Cornblath DR, Merkies IS, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. *Ann Oncol*. 2013;24:454-462.
35. Jun T, Xuequan Y, Xiaoyu W, et al. Systematic review and meta analysis on efficacy of Huangqi guizhi wuwu decoction for oxaliplatin-induced peripheral neurotoxicity. *Chin J Exp Tradit Med Formulae*. 2013;19:325-330.
36. Cheng X, Huo J, Wang D, et al. Herbal medicine AC591 prevents oxaliplatin-induced peripheral neuropathy in animal model and cancer patients. *Front Pharmacol*. 2017; 8:344.
37. Ma YQ, Chen YR, Leng YF, Wu ZW. Tanshinone IIA down-regulates HMGB1 and TLR4 expression in a spinal nerve ligation model of neuropathic pain. *Evid Based Complement Alternat Med*. 2014;2014:639563.
38. Liu Y, Wang L, Li X, Lv C, Feng D, Luo Z. Tanshinone IIA improves impaired nerve functions in experimental diabetic rats. *Biochem Biophys Res Commun*. 2010;399:49-54.
39. Di Cesare Mannelli L, Pacini A, Micheli L, et al. Astragali radix: could it be an adjuvant for oxaliplatin-induced neuropathy? *Sci Rep*. 2017;7:42021.
40. Di Cesare Mannelli L, Zanardelli M, Bartolucci G, et al. In vitro evidence for the use of astragali radix extracts as adjuvant against oxaliplatin-induced neurotoxicity. *Planta Med*. 2015;81:1045-1055.
41. Hsiang SW, Lee HC, Tsai FJ, Tsai CC, Yao CH, Chen YS. Puerarin accelerates peripheral nerve regeneration. *Am J Chin Med*. 2011;39:1207-1217.
42. Huang KS, Lin JG, Lee HC, et al. Paeoniae alba radix promotes peripheral nerve regeneration. *Evid Based Complement Alternat Med*. 2011;2011:109809.
43. Sommer C, Cruccu G. Topical treatment of peripheral neuropathic pain: applying the evidence. *J Pain Symptom Manage*. 2017;53:614-629.
44. Cheng CW, Wu TX, Shang HC, et al; CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: recommendations, explanation, and elaboration (traditional Chinese version). *Ann Intern Med*. 2017;167:W7-W20.